Search starts for new wave of Clinical Champions
Healthcare professionals who want to drive forward diabetes care are being asked to sign up to a Diabetes UK programme. The Clinical Champions initiative, which was launched in 2014, supports ...
Healthcare professionals who want to drive forward diabetes care are being asked to sign up to a Diabetes UK programme. The Clinical Champions initiative, which was launched in 2014, supports ...
A pioneering research centre aimed at finding new treatments for type 2 diabetes will be built as part of a £115m collaboration between Novo Nordisk and a leading university. Novo Nordisk has ...
Liraglutide 1.2 mg has proved “cost-effective” compared to alternative daily administered GLP-1 receptor agonists for the treatment of type 2 diabetes in the UK, a study has ...
A third of people with diabetes are risking serious complications by not taking mealtime insulin as recommended by their healthcare professional, a survey has found. One in five people also ...
A programme which provides children wth type 1 diabetes around the world free access to insulin and treatment has been extended. The Changing Diabetes® in Children initiative will continue for ...
Adults with type 2 diabetes treated with Xultophy® (insulin degludec/liraglutide) are up to 4.5 times more likely to achieve glycaemic targets without hypoglycaemia and weight gain, research has ...
The glucagonlike-peptide 2 (GLP-1) agonist liraglutide (Victoza) delays the progression of renal events, according to new research. The findings, carried out by Novo Nordisk, found particularly ...
Batches of a kit used to treat severe hypoglycaemic reactions are being recalled due to safety issues. Users of the GlucaGen HypoKit are being asked to check whether they have an affected product ...
An alternative treatment to help improve glycaemic control for adults living with diabetes is now available in Scotland. NHS Scotland can now prescribe Novo Nordisk’s Tresiba® (insulin degludec), ...
The GLP-1 receptor analogue Victoza® (liraglutide) significantly reduced the risk of major cardiovascular events and death in adults with type 2 diabetes in the LEADER trial, Novo Nordisk has ...